unither.com - UTHR Net Assets per Single Share

Graphic logo of United Therapeutics Corp. (UTHR)

United Therapeutics has established a powerful network surrounding pulmonary hypertension therapy and xenotransplantation. The book value per share on this chart demonstrates growth in net assets, where the indicator value stands at 150.02. Stability is ensured by FDA protection against generics and patient loyalty. Future potential is based on the automation of 3D bioprinting of organs, which replaces manual labor in laboratories.

United Therapeutics Corp. - UTHR Net Assets per Share (period 07/04/2022 - 10/28/2026)

Summary analytical data breakdowns for unither.com (UTHR)

- price and consensus price forecast:
Stock Price United Therapeutics Corp.|UTHR - Fair Value Consensus
- market capitalization data:
Market Value United Therapeutics Corporation|UTHR - Value Adjusted for Debt and Cash
- book capitalization data:
Net Assets per Single Share United Therapeutics|UTHR - Book Valuation of Business|Market Value to Book Value Ratio unither.com|UTHR - Total Asset Value of Company
- debt and liquidity data:
Total Debt to Capital United Therapeutics|UTHR - Long-Term Liabilities to Capital|Short-Term Debt to Capital United Therapeutics Corporation|UTHR - Company Total Debt|Debts to Book Capitalization United Therapeutics Corporation|UTHR - Long-Term Debt Volume|Company Short-Term Debts United Therapeutics
Analysis of all company metrics:United Therapeutics Corp. UTHR
Finished products of unither.com

The metric is calculated as the difference between all assets and liabilities, divided by the number of shares. This metric determines the real value of an investor's equity stake in the company, excluding market speculation. For United Therapeutics (UTHR), the stability of this value is supported by a steady cash flow from the sale of the Tyvaso DPI system. An analysis of the current book value per share on GURU.Markets allows for an assessment of the business's internal margin of safety. This indicator serves as the foundation for capital protection while awaiting the success of xenotransplantation developments.

Competitors of United Therapeutics (UTHR)

Book Value per Share Vertex Pharmaceuticals Inc. (VRTX)|ALNY: Accounting Value of a Share|Net Assets per Single Share Insmed Incorporated INSM|BMRN (biomarin.com) - Accounting Value of a Share|BBIO: Net Assets per Single Share|Net Assets per Share BGM|COGT - Net Assets per Single Share|Share Book Value Xeris Pharma (XERS)|KROS: Book Value per Share|Net Asset Value per Share arcturusrx.com ARCT|ETON: Book Value per Share|KMDA - Accounting Value per Share|Fulcrum Tx - Book Value per Share|Abeona Therapeutics Inc. (ABEO) - Net Assets per Share|MREO (Mereo BioPharma Group) - Book Value per Share|Book Value per Share PLX|Net Assets per Single Share Pliant Therapeutics (PLRX)|Net Assets per Single Share appliedtherapeutics.com (APLT)|Book Value per Share RNTX|GELS - Net Assets per Share|Accounting Value per Share Aytu Therapeutics|CMMB - Share Book Value|Book Value per Share SRXH|Polyrizon (PLRZ) - Net Asset Value per Share|Book Value per Share Aeterna Zentaris Inc (AEZS)|Equity per Share Cyclo Therapeutics, Inc (CYTH)|Inozyme Pharma, Inc. (INZY) - Accounting Value per Share|Accounting Value of a Share RPHM (reneopharma.com)|COSCIENS Biopharma (CSCI) - Net Assets per Single Share